-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IiIVjEfdPK7s/rL6TbT2QRAkEn7M19sNB9UZJSibDChAQ185k6j+RWiOxlyN0Njn cBHawtD8bAmPrZPaf8QPFw== 0001104659-07-008608.txt : 20070208 0001104659-07-008608.hdr.sgml : 20070208 20070208153607 ACCESSION NUMBER: 0001104659-07-008608 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070208 DATE AS OF CHANGE: 20070208 GROUP MEMBERS: REDCLIFFE SPC, LTD. - CLASS A SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SPECTRUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000831547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930979187 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-49329 FILM NUMBER: 07592385 BUSINESS ADDRESS: STREET 1: 157 TECHNOLOGY DR CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 9497886700 MAIL ADDRESS: STREET 1: 157 TECHNOLOGY DR CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: NEOTHERAPEUTICS INC DATE OF NAME CHANGE: 19960819 FORMER COMPANY: FORMER CONFORMED NAME: AMERICUS FUNDING CORP DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: RG CAPITAL MANAGEMENT LP CENTRAL INDEX KEY: 0001218275 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 3 BALA PLAZA EAST STE 501 CITY: BALA CYRWYD STATE: PA ZIP: 19004 BUSINESS PHONE: 6106175900 MAIL ADDRESS: STREET 1: 3 BALA PLAZA EAST STE 501 CITY: BALA CYRWYD STATE: PA ZIP: 19004 SC 13G/A 1 a07-3895_2sc13ga.htm SC 13G/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES
13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)

 

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

 

Spectrum Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, par value $.001 per share

(Title of Class of Securities)

 

84763A108

(CUSIP Number)

 

December 31, 2006

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

ý

Rule 13d-1(c)

o

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

 

CUSIP No.  84763A108

 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Radcliffe SPC, Ltd. for and on behalf of the Class A Segregated Portfolio

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Cayman Islands

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

 

6.

Shared Voting Power
476,190

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
476,190

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
476,190

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
N/A

 

 

11.

Percent of Class Represented by Amount in Row (9)
1.86%

 

 

12.

Type of Reporting Person (See Instructions)
OO

 

2


 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
RG Capital Management, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
0

 

6.

Shared Voting Power
476,190

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
476,190

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
476,190

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
N/A

 

 

11.

Percent of Class Represented by Amount in Row (9)
1.86%

 

 

12.

Type of Reporting Person (See Instructions)
PN

 

3


 

Item 1.

 

(a)

Name of Issuer
Spectrum Pharmaceuticals, Inc.

 

(b)

Address of Issuer’s Principal Executive Offices
157 Technology Drive
Irvine, California 92618

 

Item 2.

 

(a)

Name of Person Filing
See Item 2(c) below.

 

(b)

Address of Principal Business Office or, if none, Residence
See Item 2(c) below.

 

(c)

Citizenship
(1)          Radcliffe SPC, Ltd. for and on behalf of the Class A Segregated Portfolio

c/o SEI Investments Global Fund Services, Ltd.

Styne House, Upper Hatch Street

Dublin 2 Ireland

Cayman Islands segregated portfolio company

 

(2)          RG Capital Management, L.P. (1)

3 Bala Plaza East, Suite 501

251 St. Asaphs Road

Bala Cynwyd, PA 19004

Delaware limited partnership

 

(d)

Title of Class of Securities
Common Stock, par value $.001 per share (the “Common Stock”)

 

(e)

CUSIP Number
84763A108

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

(1) Pursuant to an investment management agreement, RG Capital Management, L.P. (“RG Capital”) serves as the investment manager of Radcliffe SPC, Ltd.’s Class A Segregated Portfolio.  RGC Management Company, LLC (“Management”) is the general partner of RG Capital.  Steve Katznelson and Gerald Stahlecker serve as the managing members of Management.  Each of RG Capital, Management and Messrs. Katznelson and Stahlecker disclaims beneficial ownership of the securities owned by Radcliffe SPC, Ltd. for and on behalf of the Class A Segregated Portfolio.

 

4


 

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)

Amount beneficially owned:   

See Item 4(b) below.

 

(b)

Percent of class:   

Radcliffe SPC, Ltd. for and on behalf of the Class A Segregated Portfolio (“Radcliffe”) holds warrants to acquire 476,190 shares of Common Stock (the “Warrants”).  The Warrants were purchased in a registered offering pursuant to an effective shelf registration statement on or about September 15, 2005.  The Warrants are immediately exercisable at an exercise price of $6.62 per share and expire on September 15, 2011.  The Warrants may not, however, be exercised by Radcliffe to the extent that such exercise would result in Radcliffe having beneficial ownership of more than 9.99% of the number of shares of Common Stock issued and outstanding following such exercise.  On December 31, 2006, Radcliffe beneficially owned 476,190 shares, or 1.86%, of the Issuer’s Common Stock (based on 25,093,480 shares of Common Stock outstanding as of November 2, 2006).  RG Capital Management, L.P. disclaims beneficial ownership of the securities owned by Radcliffe.

 

(c)

Number of shares as to which the person has:

 

 

 

(i)

Sole power to vote or to direct the vote:   

0

 

 

(ii)

Shared power to vote or to direct the vote:    

See Item 4(b) above.

 

 

(iii)

Sole power to dispose or to direct the disposition of:   

0

 

 

(iv)

Shared power to dispose or to direct the disposition of:   

See Item 4(b) above.

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group

Not applicable.

 

Item 9.

Notice of Dissolution of Group

Not applicable.

 

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

5


 

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Radcliffe SPC, Ltd. for and on behalf of the Class A
Segregated Portfolio

 

By: RG Capital Management, L.P.

 

By: RGC Management Company, LLC

 

 

 

By:

/s/ Gerald F. Stahlecker

 

 

 

Gerald F. Stahlecker

 

 

 

Managing Director

 

 

 

 

Dated:  February 8, 2007

 

 

 

RG Capital Management, L.P.

 

By: RGC Management Company, LLC

 

 

 

By:

/s/ Gerald F. Stahlecker

 

 

 

Gerald F. Stahlecker

 

 

 

Managing Director

 

 

 

 

Dated:  February 8, 2007

 

6


 

Exhibit 1

 

JOINT FILING AGREEMENT

 

                In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is used in the Schedule 13G) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock, par value $.001 per share, of Spectrum Pharmaceuticals, Inc., and that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.

 

                IN WITNESS WHEREOF, the undersigned hereby execute this Agreement this 8th day of February, 2007.

 

 

Radcliffe SPC, Ltd. for and on behalf of the Class A
Segregated Portfolio

 

By: RG Capital Management, L.P.

 

By: RGC Management Company, LLC

 

 

 

By:

/s/ Gerald F. Stahlecker

 

 

 

Gerald F. Stahlecker

 

 

 

Managing Director

 

 

 

 

 

 

RG Capital Management, L.P.

 

By: RGC Management Company, LLC

 

 

 

By:

/s/ Gerald F. Stahlecker

 

 

 

Gerald F. Stahlecker

 

 

 

Managing Director

 

 

7

 -----END PRIVACY-ENHANCED MESSAGE-----